Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Nrf2-IN-1
Cat. No.:
0225LY-1438
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Nrf2-IN-1 is a specialized inhibitor of nuclear factor-erythroid 2-related factor 2 (Nrf2) designed for research into the treatment of acute myeloid leukemia (AML).
Synonym:
1610022-76-8; 3-(4-Chlorophenyl)-1-[[4-(1,1-dimethylethyl)phenyl]methyl]-N-hydroxy-1H-pyrazole-5-carboxamide; 2-[(4-tert-butylphenyl)methyl]-5-(4-chlorophenyl)-N-hydroxypyrazole-3-carboxamide; 1-(4-(tert-Butyl)benzyl)-3-(4-chlorophenyl)-N-hydroxy-1H-pyrazole-5-carboxamide
CAS No.:
1610022-76-8
Compound CID:
76900951
Formula:
C21H22ClN3O2
Formula Weight:
383.87
Specification
Relative Density:
1.23 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Nrf2-IN-1 can be used in drug discovery research to study the suppression of the Nrf2 signaling pathway in resistant cancer cells.
Library Information
Target:
Nrf2
Receptor:
Keap1-Nrf2 Interface
Pathways:
Oxidative stress; Immunology/Inflammation; Chromatin/Epigenetic
Plate Number:
AOCL-19
Plate Location:
d11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
260 mg/mL; 677.31 mM
